- Conditions
- Chronic Kidney Disease
- Interventions
- MEDI8367, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2449–2472
of 7,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thyroid Cancer, Salivary Gland Cancer
- Interventions
- Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Participants
- Interventions
- E2027, E2027 matching placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Malocclusion
- Interventions
- Invisalign
- Device
- Lead sponsor
- Align Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 13
- States / cities
- Anthem, Arizona • Napa, California • Oakland, California + 10 more
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Durvalumab, Radiation Therapy, Tremelimumab
- Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
- Conditions
- Solid Tumor, Adult, NSCLC, CRC
- Interventions
- D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
- Drug
- Lead sponsor
- InventisBio Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- Fresno, California • Orange, California • San Francisco, California + 4 more
- Conditions
- Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
- Interventions
- Sirolimus, Mycophenolate mofetil (MMF), Carmustine, Etoposide, Cyclophosphamide (Cyclo, CY), FTBI
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Azenosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Interventions
- pNGVL4aCRTE6E7L2
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- PF-06291874, placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obstetric Labour, Premature
- Interventions
- GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hernia, Inguinal
- Interventions
- Robotic-assisted inguinal hernia repair
- Device
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Newport News, Virginia
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
- Interventions
- Routine/prescribed exogenous insulin dose
- Drug
- Lead sponsor
- Rachel Miller
- Other
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
- Combination Product · Drug
- Lead sponsor
- Pablo Tebas
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Interventions
- AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Cemiplimab, Cisplatin, Docetaxel
- Drug
- Lead sponsor
- Krzysztof Misiukiewicz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- SGT-003
- Genetic
- Lead sponsor
- Solid Biosciences Inc.
- Industry
- Eligibility
- 0 Years to 17 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
- Interventions
- CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
- Drug
- Lead sponsor
- Famewave Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
- Interventions
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 35
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
- Conditions
- Resectable Esophageal Cancer, GastroEsophageal Cancer
- Interventions
- Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel, Radiation
- Combination Product · Drug · Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Leukemia
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida